Setting The New Standard

Crown Laboratories and Revance Therapeutics are now united as REVANCE, providing an industry-leading, comprehensive range of aesthetics and skincare solutions.

READ THE ANNOUNCEMENT
Every Tiny Detail

The Teoxane RHA® Collection
Now with Mepivacaine

Great results don’t happen by accident. They happen by design. Introducing the first major innovation in hyaluronic acid filler anesthetic in almost two decades.

Read the announcement

OUR COMPANY

Revance is a fast-growing global aesthetics and skincare company focused on providing innovative aesthetics and market-leading skincare offerings throughout every stage of life. With a differentiated portfolio of products spanning 60 countries, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and commercialization of new products and treatments.

AESTHETICS

DAXXIFY™
PEPTIDE-POWERED NEUROMODULATOR
RHA Collection
HYALURONIC ACID FILLER
SkinPen
#1 MICRONEEDLING BRAND IN THE U.S.*§
BIOJUVE
CLINICALLY PROVEN LIVING MICROBE TECHNOLOGY*

Consumer Skincare†

PanOxyl
The Acne Authority™
StriVectin
The Science Behind Great Skin™
Blue Lizard
#1 Selling Mineral Sunscreen Brand‡
Sarna
#1 Dermatologist Recommended Topical Anti-Itch Brand‡
ZEASORB
Dermatologist Recommended Topical Powders
Desenex
Prescription Strength, Triple Action Athlete's Foot Cream and Powder
Keri
Whole body moisture therapy for dry skin relief

THERAPEUTICS

DAXXIFY™
PEPTIDE-POWERED NEUROMODULATOR

*SkinPen® Precision and BIOJUVE® are owned by Crown Aesthetics, a Revance company.

†All products under consumer skincare portfolio are owned by Crown Laboratories, Inc., a Revance company.

‡Data on File

§2024 Crown Aesthetics HCP Market Tracker, September 2024.

CAREER

Shift your career to Revance

At Revance, our success is directly shaped by our highly qualified and motivated people across our brands. We are always looking for great talent to join Revance. To learn more about a career at Revance, please visit our career page.

Revance careers

IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) for injection

Indications

(daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

IMPORTANT SAFETY INFORMATION

Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions

The most commonly observed adverse reactions are:

Glabellar lines (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Cervical Dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (6%), muscular weakness (5%), and upper respiratory tract infection (5%).

Drug Interactions

Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations

DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch

DAXI-004726

Facebook Instagram Twitter LinkedIn

FOR CUSTOMER SERVICE, PRODUCT INFORMATION, NEW ACCOUNTS OR ADVERSE EVENTS CALL: 877-3REV-NOW

1222 DEMONBREUN ST

20TH FLOOR

NASHVILLE, TN 37203

©2025 REVANCE.
RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The TEOXANE RHA® Collection is exclusively distributed by Revance®. All other trademarks are the property of their respective owners.
CORP-00147

SOCIAL MEDIA COMMUNITY GUIDELINES PRIVACY POLICY TERMS OF USE
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.